# A Clinical Trial for Examining the Therapeutic Equivalence Between Fluticasone Propionate 100 mcg and Salmeterol 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 100/50 mcg Inhalation Powder/GSK in Patients With Asthma

> **NCT03676413** · PHASE3 · COMPLETED · sponsor: **Respirent Pharmaceuticals Co Ltd.** · enrollment: 451 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** Fluticasone Propionate 100 mcg and Salmeterol 50 mcg inhalation Powder/Respirent Pharmaceuticals
- **DRUG:** ADVAIR DISKUS® 100/50 mcg inhalation powder pre-dispensed/GSK
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03676413
- **Lead sponsor:** Respirent Pharmaceuticals Co Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-10-02
- **Primary completion:** 2019-08-02
- **Final completion:** 2020-06-30
- **Target enrollment:** 451 (ACTUAL)
- **Last updated:** 2020-07-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03676413

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03676413, "A Clinical Trial for Examining the Therapeutic Equivalence Between Fluticasone Propionate 100 mcg and Salmeterol 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 100/50 mcg Inhalation Powder/GSK in Patients With Asthma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03676413. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*